We use cookies and analytics tools to improve the user experience on the Internet site and for marketing purposes. If you continue to use this site, we will assume that you agree. To the privacy policy.
Treats and limits the recurrence of eczema lesions.
Dexyane Med Eyelid Cream is a medical device* for the treatment of atopic dermatitis or contact eczema on the eyelids. The highly moisturizing formula acts like a plaster that on the one hand provides relief and reduces swelling, and on the other hand restores the skin barrier and limits bacterial adhesion. Clinically proven efficacy and good tolerance. Used alone, in combination with, or after dermocorticoids to treat eczema lesions and limit their recurrence.
Benefits:
Provides immediate relief and reduces swelling.
Restores the impaired skin barrier and corrects dryness thanks to a combination of glycerin, shea butter and triglycerides.
Protects the skin with a semi-occlusive protective film made from a polysaccharide network.
Limits bacterial adhesion (S. aureus is potentially involved in the superinfection of lesions).
*Dexyane Med Eyelid Cream is a medical device that meets the legal requirements of the EU Medical Device Regulation and is therefore CE marked. Please read the instructions in the package leaflet carefully. Do not use during pregnancy or breastfeeding. Avoid direct contact with the eyes. Suitable from 3 months of age.
Dexyane Med Cream
Treats and limits the recurrence of eczema lesions
Dexyane Med Cream for face, body and hands. Medical device* for the treatment of atopic dermatitis and contact eczema, promotes healing and limits recurrence. Relieves itching and reduces the intensity of inflammatory signs in eczema on the body, face and hands. Used alone, in combination with and/or after dermocorticoids.
Benefits:
Relieves itching.
Treats eczema lesions.
Limits the recurrence of eczema lesions.
*Dexyane Med Cream for face, body and hands is a medical device that meets the legal requirements of the EU Medical Device Regulation and is therefore CE marked. Please read the instructions in the package leaflet carefully. Do not use during pregnancy or breastfeeding, on mucous membranes or in the diaper area of infants. Avoid direct contact with the eyes. Suitable from 3 months of age.
Expert advice by a pharmacist: info@haar-shop.ch / 033 550 30 30 (Mon – Fri | 08:00 – 18:00)
Product characteristics
Brand
Ducray
How to use
Dexyane Med Eyelid Cream
Apply twice daily in a thin layer with a clean finger directly onto inflammatory lesions of the eyelid, avoiding contact with the eye. For external use only.
Use alone, in combination with, and/or after dermocorticosteroids.
When used in combination with a dermocorticosteroid, apply the dermocorticosteroid and wait a few minutes (5–15 minutes) before applying Dexyane Med Eyelid Cream.
Consult your doctor regarding the use of Dexyane Med Eyelid Cream with the prescribed dermocorticosteroid in infants aged ≥ 3 months and children.
If symptoms do not disappear after three weeks of treatment, a doctor should be consulted.
Dexyane Med Cream
Apply twice daily directly onto the inflammatory eczema lesions.
Use alone, in combination with, and/or after dermocorticosteroids.
When used in combination with a dermocorticosteroid, apply the dermocorticosteroid and wait a few minutes (5–15 minutes) before applying Dexyane Med Cream.
Do not use if you are allergic to any of the ingredients.
Consult a doctor if allergic reactions occur.
Avoid contact with the eyes to prevent irritation.
If contact with the eyes occurs, rinse immediately with clear water.
Consult a doctor if eye irritation persists.
Do not use during pregnancy or breastfeeding.
Keep out of reach of children.
Do not apply on the diaper area or mucous membranes.
Do not treat more than 30% of the body surface area.
Close the tube tightly after use.
Skin reactions at the application site (burning, tingling, erythema, itching, dryness...) are expected in patients with eczema due to impaired skin barrier. Temporary worsening of eczema may occur. If there is no improvement or if eczema symptoms worsen within 8–10 days, a doctor should be consulted.
If you suspect a serious incident related to the use of the medical device has occurred, please report it to the relevant national authority and the manufacturer.
https://www.haar-shop.ch/en/76216106-ekzema-set.html92158Eczema Sethttps://www.haar-shop.ch/media/catalog/product/thumbnail/0d86eab85e8e6855be8b0e6e654395ab8b3ca3c110ed4ce356c455f4/small_image/0/448x448/001/99/3/6/3697769fee175895f6b2f4c99ff4f80dcb3bdff6_0698596282216_bi_ducray_ekzema_set.jpg45.7545.75CHFInStock/Brands/Care/Care/Facial care/Care/Facial care/Day care/Care/Facial care/Eye care/Dermatology/Dermatology/Face/Dermatology/Body/Dermatology/Face/Day care/Dermatology/Face/Eye care/Dermatology/Body/Hand care/Care/Hand care/Care/Hand care/Hand cream/Brands/Ducray/Brands/Ducray/Eczema/Make-up & nails/Make-up & nails/Nail care /Make-up & nails/Nail care /Hand & foot care2918997197397527002701270227052707272034353437550255291991031428212189971270027012702343595502<p><strong>The set contains:</strong></p><ul><li>Dexyane Med Eyelid Cream (15 ml)</li><li>Dexyane Med Cream (30 ml)<br></li></ul><p>
<strong><br></strong></p><p><b>Dexyane Med Eyelid Cream
<br></b></p><p><strong>Treats</strong> and <strong>limits</strong> the recurrence of <strong>eczema lesions</strong>.</p>
<p>Dexyane Med Eyelid Cream is a medical device* for the treatment of <strong>atopic dermatitis</strong> or <strong>contact eczema</strong> on the eyelids. The highly moisturizing formula acts like a plaster that on the one hand provides <strong>relief</strong> and <strong>reduces swelling</strong>, and on the other hand <strong>restores the skin barrier</strong> and limits bacterial adhesion. Clinically proven efficacy and good tolerance. Used alone, in combination with, or after dermocorticoids to treat eczema lesions and limit their recurrence.</p>
<p> </p>
<p><strong>Benefits:</strong></p>
<ul>
<li>Provides immediate relief and reduces swelling.</li>
<li>Restores the impaired skin barrier and corrects dryness thanks to a combination of glycerin, shea butter and triglycerides.</li>
<li>Protects the skin with a semi-occlusive protective film made from a polysaccharide network.</li>
<li>Limits bacterial adhesion (S. aureus is potentially involved in the superinfection of lesions).</li>
</ul>
<p> </p>
<p> </p>
<p><em>*Dexyane Med Eyelid Cream is a medical device that meets the legal requirements of the EU Medical Device Regulation and is therefore CE marked. Please read the instructions in the package leaflet carefully. Do not use during pregnancy or breastfeeding. Avoid direct contact with the eyes. Suitable from 3 months of age.</em></p><p><em><br></em></p><p><b>Dexyane Med Cream
<em><br></em></b></p><p><strong>Treats and limits the recurrence of eczema lesions</strong></p>
<p>Dexyane Med Cream for face, body and hands. Medical device* for the treatment of <strong>atopic dermatitis</strong> and <strong>contact eczema</strong>, promotes healing and <strong>limits recurrence</strong>. <strong>Relieves itching</strong> and reduces the intensity of inflammatory signs in eczema on the body, face and hands. Used alone, in combination with and/or after dermocorticoids.</p>
<p><br></p>
<p><strong>Benefits:</strong></p>
<ul>
<li>Relieves itching.</li>
<li>Treats eczema lesions.</li>
<li>Limits the recurrence of eczema lesions.</li>
</ul>
<p><br></p>
<p><br></p>
<p><em>*Dexyane Med Cream for face, body and hands is a medical device that meets the legal requirements of the EU Medical Device Regulation and is therefore CE marked. Please read the instructions in the package leaflet carefully. Do not use during pregnancy or breastfeeding, on mucous membranes or in the diaper area of infants. Avoid direct contact with the eyes. Suitable from 3 months of age.</em></p><div><br></div><div><img src="data:image/png;base64,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" data-filename="download.png" style="width: 33px;"> <strong>Expert advice by a pharmacist:<a href="mailto:%20info@haar-shop.ch" target="_blank"> info@haar-shop.ch</a> / 033 550 30 30</strong> (Mon – Fri | 08:00 – 18:00)<br></div>
DucrayCHF00add-to-cartprodukt_serie:Dexyanesku:76216106not_in_nosto:Nodd_deal:dd_items:0dd_from:dd_initialAmount:dd_to:dd_price:dd_displayType:badge_counterhttps://www.haar-shop.ch/media/catalog/product/thumbnail/fd9759f72ee4b9de8675501c85127275b7c46a7ddb16cbeb1a73348f/small_image/0/224x224/001/99/3/6/3697769fee175895f6b2f4c99ff4f80dcb3bdff6_0698596282216_bi_ducray_ekzema_set.jpgNoDexyane76216106Eczema SetSetDucray53.8000000698596282216NoNoNo30 ml + 15 mlNo2025-10-01 00:00:002025-12-01 00:00:00NoYesEnabledCatalog, Searchsimple2012025-08-16
We ship with
Payment
Invoice
Cash in advance
Responsibility
Compensated CO2 emission by haar-shop.ch: 1'100'000 kg
Expert advice by a pharmacist:
